Now Available:
Watch video podcasts of the 2008 EULAR press conferences

CME Opportunity:

Arthritis: Ligaments Tie Together OA Pathology
Ligaments are emerging as the key to understanding why osteoarthritis develops in nontraumatized joints...

Arthritis: Naproxcinod Moves Ahead in Pivotal Phase III Study in Osteoarthritis
The next generation of COX inhibitors is likely to include the nitric oxide-donating CINODs, the first of which (naproxcinod) is in phase III trials...

Consumer News: Success Rate Rising of Transplants Using Donor Tissues
Despite hurdles such as high costs and the dangers of immunosuppression following surgery, composite tissue allotransplantation (CTA) is becoming a more popular procedure...

BioPharm Business: Logical Therapeutics Reports Positive Results from Phase Ib Clinical Study of Naproxen Prodrug; Dosing Well-Tolerated and Plasma Concentrations Achieve Therapeutic Range
In the phase Ib study twice-daily dosing with LT-NS001 for 7 days resulted in plasma concentrations of naproxen within the therapeutic range, with no serious adverse events reported...

Click here to remove your e-mail address from our mailing list. For questions and comments regarding this newsletter please contact .